BioMarin Pharmaceutical Inc. is a world leader in developing and commercialising first- or best-in-class therapies for rare genetic diseases. C‐type natriuretic peptide (CNP) is a growth factor with receptors expressed in many cells and systems throughout the body (e.g., cardiovascular, pulmonary, central nervous system (CNS), musculoskeletal and reproductive tissues). BioMarin Pharmaceutical Inc. is seeking early research ideas and preclinical proposals for CNP‐related research projects.
Comments are closed.